STAAR Surgical (STAA)
(Delayed Data from NSDQ)
$42.86 USD
+1.84 (4.49%)
Updated May 9, 2024 04:00 PM ET
After-Market: $42.87 +0.01 (0.02%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
STAA 42.86 +1.84(4.49%)
Will STAA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for STAA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STAA
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
Wall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings
STAA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dentsply International (XRAY) Meets Q1 Earnings Estimates
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
Strength Seen in West Pharmaceutical (WST): Can Its 5.7% Jump Turn into More Strength?
Other News for STAA
Oppenheimer Sticks to Its Hold Rating for Staar Surgical (STAA)
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Staar Surgical: A Hold Rating Amidst Conservative Guidance and Modest Growth Prospects
What 7 Analyst Ratings Have To Say About Staar Surgical
Staar Surgical price target lowered by $3 at Canaccord, here's why